ArticleInternational journal of hematology2016

Phase I study of once weekly treatment with bortezomib in combination with lenalidomide and dexamethasone for relapsed or refractory multiple myeloma.

Haruhito Totani et al.PubMed ↗Publisher ↗

No numbers read from the abstract.